European Archives - Page 596 of 1189 - European Medical Journal

Migratory Loose Bodies from the Ankle Joint into the Flexor Hallucis Longus Tendon Sheath

Communication between the flexor hallucis longus (FHL) tendon sheath and the ankle joint is well-recognised and is reportedly present in around 17% of individuals.

New Information on How COVID-19 Affects Human Kidney Cells

The researchers discovered that although the virus enters, infects, and replicates in human kidney cells, this did not always lead to cell death…

Is Coffee Consumption Associated with Risk of Chronic Kidney Disease?

Metabolites in the blood have been analysed, with their levels altered by coffee consumption, and an association with developing chronic kidney disease…

Replacing Hubris with Humility

A talk to Chip Helm, Author, and Account Executive, Cook Medical about leadership, personal branding, and how to sell yourself with humility.

EMJ Nephrology 9 [Supplement 4] 2021 Feature Image

EMJ Nephrology 9 [Supplement 4] 2021

CHRONIC kidney disease (CKD) affects approximately 700 million individuals worldwide. Many patients with CKD require haemodialysis, and more than two-thirds of these patients have CKD-associated pruritus (CKD-aP). CKD-aP can be bothersome for many patients and drastically affect quality of life, from causing sleep issues to mental health problems. Almost 40% of dialysis patients are at least ‘moderately’ bothered and 19% of patients are at least very much bothered by pruritus.

EMJ Nephrology 9 [Supplement 4] 2021 Feature Image

Chronic Kidney Disease-Associated Pruritus: From Epidemiology to Treatment

Chronic kidney disease-associated pruritus (CKD-aP) occurs in over two-thirds of patients undergoing haemodialysis. The aetiology of CKD-aP may be multifactorial, involving immune system and opioid dysregulation, peripheral neuropathy, and toxin deposition. CKD-aP can be extremely bothersome for some patients, affecting health-related quality of life and sleep, as well as increasing the likelihood of hospitalisation, infections, and death.

EMJ Neurology 9 [Supplement 3] 2021

‘Emerging Treatment Strategies for Motor Fluctuation Management: Therapeutic Options for Newly Detected Motor Fluctuations’ reviews…

Emerging Treatment Strategies for Motor Fluctuation Management: Therapeutic Options for Newly Detected Motor Fluctuations

At the 7th Congress of the European Academy of Neurology (EAN), held virtually in June 2021, real-world data on the efficacy and safety of…

EMJ Hematology 9 [Supplement 5] 2021 feature image

Real World Evidence in Acute Myeloid Leukaemia

In recent years, there has been an increasing appreciation of the role that patient characteristics such as age, gender…

EMJ Hematology 9 [Supplement 5] 2021 feature image

EMJ Hematology 9 [Supplement 5] 2021

In this interview, two experts in the field of acute myeloid leukaemia (AML), Jean-Baptiste Micol, University of Paris-Saclay, France, and Thomas Cluzeau, University Hospital of Nice, France, share their views and debate the current landscape of real-world data in AML research and treatment.